These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17678425)

  • 1. Therapeutic approaches for prion disorders.
    Ludewigs H; Zuber C; Vana K; Nikles D; Zerr I; Weiss S
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):613-30. PubMed ID: 17678425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches targeting the prion receptor LRP/LR.
    Zuber C; Ludewigs H; Weiss S
    Vet Microbiol; 2007 Aug; 123(4):387-93. PubMed ID: 17498894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases.
    Sakaguchi S; Ishibashi D; Matsuda H
    Expert Opin Ther Pat; 2009 Jul; 19(7):907-17. PubMed ID: 19514955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of non-prion biomarkers for the diagnosis of Transmissible Spongiform Encephalopathies in the live animal.
    Parveen I; Moorby J; Allison G; Jackman R
    Vet Res; 2005; 36(5-6):665-83. PubMed ID: 16120244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is vaccination against transmissible spongiform encephalopathy feasible?
    Wisniewski T; Chabalgoity JA; Goni F
    Rev Sci Tech; 2007 Apr; 26(1):243-51. PubMed ID: 17633306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy.
    Vana K; Zuber C; Nikles D; Weiss S
    Cell Mol Neurobiol; 2007 Feb; 27(1):107-28. PubMed ID: 17151946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prion diseases in Japan: analysis of 918 patients].
    Yamada M
    Rinsho Shinkeigaku; 2007 Nov; 47(11):805-8. PubMed ID: 18210803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of molecular target based-therapy for prion diseases].
    Sakasegawa Y; Doh-ura K
    Brain Nerve; 2007 Apr; 59(4):405-14. PubMed ID: 17447527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases.
    Liberski PP; Sikorska B; Hauw JJ; Kopp N; Streichenberger N; Giraud P; Budka H; Boellaard JW; Brown P
    Virus Res; 2008 Mar; 132(1-2):226-8. PubMed ID: 18164506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different prion conformers target the olfactory pathway in sporadic Creutzfeldt-Jakob disease.
    Zanusso G; Ferrari S; Benedetti D; Sbriccoli M; Rizzuto N; Monaco S
    Ann N Y Acad Sci; 2009 Jul; 1170():637-43. PubMed ID: 19686205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues.
    Cordes H; Bergström AL; Ohm J; Laursen H; Heegaard PM
    J Immunol Methods; 2008 Sep; 337(2):106-20. PubMed ID: 18657541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and limits of TSE diagnostic tools.
    Grassi J; Maillet S; Simon S; Morel N
    Vet Res; 2008; 39(4):33. PubMed ID: 18284910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal function and morphology are altered in cattle infected with the prion disease transmissible mink encephalopathy.
    Smith JD; Greenlee JJ; Hamir AN; Richt JA; Greenlee MH
    Vet Pathol; 2009 Sep; 46(5):810-8. PubMed ID: 19429980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prions: protein aggregation and infectious diseases.
    Aguzzi A; Calella AM
    Physiol Rev; 2009 Oct; 89(4):1105-52. PubMed ID: 19789378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Washington statewide pathology surveillance for prion disease.
    Allen CT; Sonnen J; Leslie MJ; Kidoguchi L; Harris C; Gambetti P; Montine TJ
    Ann Neurol; 2007 Apr; 61(4):371-2. PubMed ID: 17358023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy in prion diseases.
    Forloni G; Artuso V; Roiter I; Morbin M; Tagliavini F
    Curr Top Med Chem; 2013; 13(19):2465-76. PubMed ID: 24059336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid dual staining procedure for the quantitative discrimination of prion amyloid from tissues reveals how interactions between amyloid and lipids in tissue homogenates may hinder the detection of prions.
    Hervé R; Collin R; Pinchin HE; Secker T; Keevil CW
    J Microbiol Methods; 2009 Apr; 77(1):90-7. PubMed ID: 19318058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prion diseases: disease diversity and therapeutics].
    Doh-ura K
    Rinsho Shinkeigaku; 2004 Nov; 44(11):855-6. PubMed ID: 15651313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.